Early Efficacy Signal

The most likely path is that Radical Numerics releases encouraging but preliminary clinical data showing the AI-designed phage cocktail reduced or cleared the target infection without serious safety issues. This would validate the AI-phage concept, help de-risk phage therapy platforms, and increase investor attention on companies already in antibacterial phage trials.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.